2022 ESC/ERS Four-Strata PAH Risk Assessment Calculator

Clinical calculation support · Verify results before clinical use

Four-Strata Risk Assessment

Enter all three variables to estimate the patient's follow-up PAH risk category.

— Risk grade
1

WHO Functional Class (WHO-FC)

Select the current World Health Organization functional class.

WHO-FC I and II are both assigned 1 point; Class III = 3 points; Class IV = 4 points.
2

Six-Minute Walking Distance (6MWD)

Enter the distance walked during the standardized 6-minute walk test.

Risk grades: >440 m = 1; 320–440 m = 2; 165–319 m = 3; <165 m = 4.
3

Natriuretic Peptide

Choose one biomarker assay and enter its measured concentration.

BNP and NT-proBNP use different cut-offs. Use the assay actually measured; do not convert one marker into the other.
— Mean grade
Overall PAH risk category
Awaiting complete assessment
Complete all three variables to calculate the four-strata risk category.
WHO-FC grade—
6MWD grade—
Biomarker grade—
This simplified tool supports follow-up risk assessment and does not replace comprehensive clinical evaluation.

About the Four-Strata PAH Risk Assessment

The 2022 ESC/ERS four-strata model is a simplified, non-invasive risk-assessment tool for patients with pulmonary arterial hypertension (PAH), particularly during follow-up. It uses WHO-FC, 6MWD, and BNP or NT-proBNP to classify patients into low, intermediate-low, intermediate-high, or high risk.

Each variable is assigned a grade from 1 to 4. The arithmetic mean of the three grades is calculated and rounded to the nearest integer (half values rounded upward) to determine the overall risk category.

Risk grading criteria

VariableLow (1)Intermediate-low (2)Intermediate-high (3)High (4)
WHO-FCI or II—IIIIV
6MWD (m)>440320–440165–319<165
BNP (ng/L)<5050–199200–800>800
NT-proBNP (ng/L)<300300–649650–1100>1100

Important application notes

  • This model is recommended as a basic risk-stratification tool during follow-up, not as a substitute for comprehensive initial assessment at diagnosis.
  • The four-strata model was developed and validated using all three variables. The standard calculation in this tool therefore requires WHO-FC, 6MWD, and BNP or NT-proBNP.
  • The key COMPERA 2.0 development cohort consisted of adults with PAH and excluded other forms of pulmonary hypertension, Eisenmenger syndrome, and confirmed or suspected pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis; applicability outside the studied population requires caution.
  • Consider additional clinical information, including right-heart imaging, haemodynamics, disease aetiology, age, sex, comorbidities, and renal function.
  • The biomarker cut-offs are assay-specific categories in ng/L. BNP and NT-proBNP are not interchangeable.

References

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal. 2022;61(1):2200879. DOI: 10.1183/13993003.00879-2022.
Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. European Respiratory Journal. 2022;60(1):2102311. DOI: 10.1183/13993003.02311-2021.
Boucly A, Weatherald J, Savale L, et al. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. European Respiratory Journal. 2022;59(6):2102419. DOI: 10.1183/13993003.02419-2021.
Clinical disclaimer: This calculator provides a simplified risk classification and is intended to support, not replace, clinical judgement. Risk category alone must not determine treatment decisions. Interpret results in the context of the patient's overall clinical status and the full PAH assessment, including imaging and haemodynamic findings where appropriate.